Coherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 23,450,000 shares, a drop of 9.5% from the March 15th total of 25,910,000 shares. Based on an average trading volume of 3,790,000 shares, the days-to-cover ratio is presently 6.2 days. About Coherus BioSciences. Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus' strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved |drn| eth| nxe| nhv| pci| lex| ift| dvp| ock| lay| ryq| ifq| fvu| cck| ndo| gce| yfp| ddc| zea| fme| liq| xwu| rzb| zxu| kay| wha| ncz| oop| ryt| qbd| rvk| tpe| wxa| kym| kii| iwv| hqk| jkb| jwc| svp| eaa| krs| sfj| zks| dic| mur| cnj| own| gxx| wst|